Could Dupixent (dupilumab) ever be turned into an oral pill?
Dupixent is currently a biologic (dupilumab), which is an injectable monoclonal antibody. In general, monoclonal antibodies are not made into conventional “pills” because the digestive tract breaks down proteins, and the drug would not be absorbed effectively by mouth.
With only the information provided here, there is no basis to say that Dupixent will be developed as an oral pill.
Are there any reasons it might stay injectable long-term?
Dupixent’s mechanism depends on delivering the full antibody into the body so it can bind its target. That’s the key reason it’s formulated as a subcutaneous injection today, and it’s also why switching to a pill would be a major formulation and development shift.
What drug types could become pills instead of switching Dupixent?
Even if Dupixent itself stays injectable, some companies develop different therapies in the same disease area that are small molecules or otherwise designed for oral dosing. Those would be “different drugs,” not a different dosage form of Dupixent.
What would you need to see to know a pill is actually coming?
If a company pursued an oral version, you would usually expect to see:
- Public clinical development announcements for an oral candidate tied to dupilumab’s target biology (or a clearly stated reformulation strategy).
- Regulatory filings and trial results specific to an oral product, not just updated injection schedules or devices.
If you share what condition you use Dupixent for (e.g., asthma, eczema/atopic dermatitis, nasal polyps), I can help narrow what the most likely alternatives or future oral directions are for that specific area.